... motions to dismiss similar reverse-payment allegations.! None ...

... None ...

... none of the Generic Defendants could ...

Plaintiffs nonetheless 26 Case 1:20-cv-05735-LJL Document 363 Filed 02/09/22 Page 35 of 68 insist that the transaction provided Watson with a net payment too, alleging that the mutual releases were worth more than Watson paid for ...

None of the three Glenmark entities that signed the Forest/Glenmark Settlement Agreement (GGL, GPL and GGI) is a party to the Collaboration and Option Agreement; likewise, GPSA is not a party to the Forest/Glenmark Settlement ...

This Document Relates to: All Direct Purchaser Actions CVS & Rite Aid (No. 1:20-cv-10087-LJL) Walgreen (No. 1:20-cv-09793-LJL)

COMPLAINTS PURSUANT TO FEDERAL RULE OF CIVIL PROCEDURE 12(b)(6) I, Peter J. Carney, declare as follows:

I submit this declaration in support of Defendants’ Motion to Dismiss the Direct Purchaser and Retailer Plaintiffs’ Second Amended Complaints Pursuant to Federal Rule of Civil Procedure 12(b)(6).

Exhibit 6 is a true and correct copy of a Termination and Release Agreement dated November 4, 2013 between Moksha8, Inc., Moksha8 Farmaceutica, S. de R.L.

de C.V., Moksha8 Brasil Distribuidora e Representacao de Medicamentos Ltda., Arrow International Ltd., and Actavis, Inc., beginning with the bates number FOR-BYS-00000361, and produced by the Forest Defendants in this litigation.

In Re Bystolic Antitrust Litigation This Document Relates To: All Actions

PLEASE TAKE NOTICE THAT the undersigned, of the law firm of Orrick, Herrington & Sutcliffe LLP, is admitted to practice in this court and is hereby entering an appearance as counsel of record for Defendant ANI Pharmaceuticals, Inc. in the above-captioned matter.

... regard to the strength of the Generic Competitors’ challenges to the ’040 Patent, Bystolic would have no generic competitors and Forest would maintain patent-generated monopoly profits until at least September 17, 2021, and none ...

TOWHIDIAN, M.D., On Behalf Of Themselves And All Others Similarly Situated, Plaintiffs, vs.

For the reasons set forth in the Order Granting Plaintiffs’ Motion For Final Approval Of Class Settlement and Granting Plaintiffs’ Motion For Attorneys’ Fees, Costs, And Incentive Awards entered on August 27, 2018 [Dkt. No. 397], all claims against Defendant Allergan, Inc. are dismissed with prejudice as to the Class Representatives and as to all Class Members, except those Class Members identified in Exhibit C to Declaration of Rachel Christman Re: Notice And Settlement Administration [Dkt. No. 392-3] as having timely requested exclusion from the Class.

Except for the Class Members identified in Exhibit C to the Christman Declaration, each Class Member shall be deemed to have granted the Released Parties as defined in Section 11(a) of the Settlement Agreement a release of claims in accordance with Sections 11(a)-11(b) of the Settlement Agreement.

The Clerk is directed to enter this Final Judgment pursuant to Federal Rule of Civil Procedure 54(a).

Josephine L. Staton, United States District Judge

Both parties move for summary judgment on, among other grounds, the issue of causation, i.e., whether Allergan’s alleged anticompetitive conduct caused Plaintiffs’ injuries.

Plaintiffs’ expert Dr. John Geigert posits that FDA approval for MT-10109L could reasonably have been achieved by mid-2015 if Medytox had been able to pursue a more efficient strategy for manufacturing clinical and commercial products.

However, Medytox was unable to pursue its preferred strategy in accordance with Dr. Geigert’s timeline because the agreement allocates responsibility for navigating the FDA approval process exclusively to Allergan.

Plaintiffs should present an evidence-supported graphic timeline that identifies every step that Medytox would had to have taken from the time of the agreement1 in order to successfully bring MT-10109L to market by mid-2015.

To the extent possible, Plaintiffs should assign a probability, up to and including a percentage likelihood, that each step would successfully occur within the time allotted in the timeline.